Wang YC - Search Results

1

Acquisition of tumorigenic potential and enhancement of angiogenesis in pulmonary stem/progenitor cells through Oct-4 hyperexpression.

Gu SY, Ho CC, Huang YK, Chen HW, Wang YC, Kuo CY, Teng SC, Fu WM, Yang PC, Wu CW, Peng FC, Ling TY. Gu SY, et al. Among authors: wang yc. Oncotarget. 2016 Mar 22;7(12):13917-31. doi: 10.18632/oncotarget.7285. Oncotarget. 2016. PMID: 26871601 Free PMC article.

2

Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells.

Wang YC, Chao TK, Chang CC, Yo YT, Yu MH, Lai HC. Wang YC, et al. PLoS One. 2013 Sep 18;8(9):e74538. doi: 10.1371/journal.pone.0074538. eCollection 2013. PLoS One. 2013. PMID: 24058587 Free PMC article.

3

Ovarian cancer stem-like cells show induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor.

Liu KC, Yo YT, Huang RL, Wang YC, Liao YP, Huang TS, Chao TK, Lin CK, Weng SJ, Ma KH, Chang CC, Yu MH, Lai HC. Liu KC, et al. Among authors: wang yc. Oncotarget. 2013 Dec;4(12):2366-82. doi: 10.18632/oncotarget.1424. Oncotarget. 2013. PMID: 24280306 Free PMC article.

4

Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer.

Lin CK, Bai MY, Hu TM, Wang YC, Chao TK, Weng SJ, Huang RL, Su PH, Lai HC. Lin CK, et al. Among authors: wang yc. Oncotarget. 2016 Feb 23;7(8):8993-9006. doi: 10.18632/oncotarget.7113. Oncotarget. 2016. PMID: 26848771 Free PMC article.

5

Growth inhibition of ovarian tumor-initiating cells by niclosamide.

Yo YT, Lin YW, Wang YC, Balch C, Huang RL, Chan MW, Sytwu HK, Chen CK, Chang CC, Nephew KP, Huang T, Yu MH, Lai HC. Yo YT, et al. Among authors: wang yc. Mol Cancer Ther. 2012 Aug;11(8):1703-12. doi: 10.1158/1535-7163.MCT-12-0002. Epub 2012 May 10. Mol Cancer Ther. 2012. PMID: 22576131

6

Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma.

Wang WL, Chang WL, Yang HB, Wang YC, Chang IW, Lee CT, Chang CY, Lin JT, Sheu BS. Wang WL, et al. Among authors: wang yc. Oncotarget. 2016 Nov 1;7(44):71169-71181. doi: 10.18632/oncotarget.8460. Oncotarget. 2016. PMID: 27036032 Free PMC article.

7

An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients.

Chang PY, Liao YP, Wang HC, Chen YC, Huang RL, Wang YC, Yuan CC, Lai HC. Chang PY, et al. Among authors: wang hc, wang yc. Oncotarget. 2017 Jun 16;8(32):53432-53449. doi: 10.18632/oncotarget.18515. eCollection 2017 Aug 8. Oncotarget. 2017. PMID: 28881822 Free PMC article.

8

GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.

Chen HJ, Huang RL, Liew PL, Su PH, Chen LY, Weng YC, Chang CC, Wang YC, Chan MW, Lai HC. Chen HJ, et al. Among authors: wang yc. Int J Cancer. 2018 Dec 15;143(12):3106-3119. doi: 10.1002/ijc.31750. Epub 2018 Oct 3. Int J Cancer. 2018. PMID: 30006927

9

ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome.

Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, Su PH, Lai HC. Wang YC, et al. Am J Pathol. 2012 Mar;180(3):1159-1169. doi: 10.1016/j.ajpath.2011.11.015. Epub 2012 Jan 2. Am J Pathol. 2012. PMID: 22222226 Free article.

10

LIM-homeobox transcription factor 1, alpha (LMX1A) inhibits tumourigenesis, epithelial-mesenchymal transition and stem-like properties of epithelial ovarian cancer.

Chao TK, Yo YT, Liao YP, Wang YC, Su PH, Huang TS, Lai HC. Chao TK, et al. Among authors: wang yc. Gynecol Oncol. 2013 Mar;128(3):475-82. doi: 10.1016/j.ygyno.2012.12.018. Epub 2012 Dec 24. Gynecol Oncol. 2013. PMID: 23270808

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,540 results

Search Page

Filters